Currently Browsing CPLRG™ by: Case Number
Browse By: Case Date | Case Name
- Pages:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- ...
- 16
- »
CPLRG™ 0002 - Advanced Software Design Corp. v. Federal Reserve Bank of St. Louis - Sep. 30, 2009
Advanced Software Design Corp. v. Federal Reserve Bank of St. Louis, 583 F.3d 1371, CPLRG 0002 (Fed. Cir. 2009) (NEWMAN, Prost & Moore) advancedsoftware09302009
MAJOR ISSUES: United States Government–Use for the Government with its “Authorization or Consent.”
Read CPLRG™ 0002
CPLRG™ 0003 - Board of Trustees of The Leland Stanford Junior University v. Roche Molecular Systems, Inc. - Sep. 30, 2009
Board of Trustees of The Leland Stanford Junior University v. Roche Molecular Systems, Inc., 583 F.3d at 832, CPLRG 0003 (Fed. Cir. 2009) (LINN, Prost & Moore), aff’d, 131 S. Ct. 502 (2011) stanfordroche093020091
MAJOR ISSUES: Standing–Ownership Counterclaim by Accused Infringer–State Statute of Limitations
Assignment Agreement–Assignment of Present Interest in Future Inventions–Equitable Title–Earlier Agreement to Assign Right in the Future–Bona Fide Purchaser–Bayh-Dole Act
Update: On June 6, 2011, the Supreme Court affirmed this decision. See CPLRG 0070.
Read CPLRG™ 0003
CPLRG™ 0004 - Janssen Pharmaceutica N.V. v. Teva Pharmaceuticals USA, Inc. - Sep. 25, 2009
583 F.3d 1317, 2009 U.S. App. LEXIS 21166 (Fed. Cir. 2009) (DYK & Mayer; GAJARSA, dissenting)
janssenteva09252009
MAJOR ISSUES: Utility–Enablement–Method of Treating Disease
Read CPLRG™ 0004
CPLRG™ 0005 - AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA, Inc. - Sep. 25, 2009
AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA, Inc., 583 F.3d 766, CPLRG 0005 (Fed. Cir. 2009) astrazenecateva09252009
MAJOR ISSUES: inequitable conduct, no intent to deceive, disclosure of comparative data as requested by examiner to overcome obviousness rejection, failure to disclose internal data on other related compounds, failure to synthesize compounds for comparative testing
Read CPLRG™ 0005
CPLRG™ 0006 - Iovate Health Sciences, Inc. v. Bio-Engineered Supplements & Nutrition, Inc. - Nov. 19, 2009
586 F.3d 1376, 2009 U.S. App. LEXIS 25388 (Fed. Cir. 2009)
iovatehealthfc
MAJOR ISSUES: Anticipation–lack of novelty
Printed publication more than a year before patent application filing–Section 102(b)
Advertisement in a trade magazine
Enablement
Read CPLRG™ 0006
Currently Browsing CPLRG™ by: Case Number
Browse By: Case Date | Case Name
- Pages:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- ...
- 16
- »